EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer

Michiel Vlaming iD, Wouter Koole, R Jeroen A van Moorselaar, Eveline M A Bleiker, Ellen van de Geer, Hanneke W M van Deutekom iD, Marjolijn J L Ligtenberg, Klaartje van Engelen, C Marleen Kets, Lizet E van der Kolk, Gina Schijven, Niven Mehra und 5 weitere

BJU International · 2025

DOI: 10.1111/bju.16916 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2025. Verfasst von Michiel Vlaming und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Germ-Line Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa). Patients and methods In this prospective multicentre cohort study ( n = 15 centres), germline genetic testing of the genes BRCA1 , BRCA2 , ATM , CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non‐oncological conditions. Additionally, we identified factors that increased the likelihood of carrying a gPV.

Results

A total of 779 patients with mPCa underwent germline genetic testing, of whom 46 (5.9%) had a gPV in a DNA damage repair gene. Most gPVs were found in CHEK2 (1100delC variant), ATM and BRCA2 , all significantly more prevalent than in the reference population (odds ratios 2.4, 2.8 and 3.1, respectively). The prevalence of gPVs in BRCA1 and PALB2 was not significantly increased. Patients with a second primary cancer, a first‐ or second‐degree relative with breast cancer at age < 50 years, or pancreatic cancer, or Jewish ancestry had the highest likelihood of carrying a gPV.

Conclusion

We found that gPVs in CHEK2 , ATM and BRCA2 were associated with men presenting with mPCa. Several factors increased the likelihood of carrying such a variant and, in these cases, healthcare professionals should be aware of the need to offer germline genetic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGerm-Line MutationHumansMaleMiddle AgedProspective StudiesAgedPrevalenceAtaxia Telangiectasia Mutated ProteinsCheckpoint Kinase 2Fanconi Anemia Complementation Group N ProteinNetherlandsGenetic TestingBRCA1 ProteinFemaleGenetic Predisposition to DiseaseBRCA2 Protein

Stichwörter der Autor:innen

breast cancercascade testinggermline pathogenic varianthereditymetastatic prostate cancer

Substanzen

CHEK2 protein, humanAtaxia Telangiectasia Mutated ProteinsATM protein, humanCheckpoint Kinase 2PALB2 protein, humanFanconi Anemia Complementation Group N ProteinBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
  • Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Clinical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Michiel Vlaming, Hanneke W M van Deutekom

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Vlaming, M., Koole, W., van Moorselaar, R. J. A., Bleiker, E. M. A., van de Geer, E., van Deutekom, H. W. M., Ligtenberg, M. J. L., van Engelen, K., Kets, C. M., van der Kolk, L. E., Schijven, G., Mehra, N., Noordzij, M. A., Meijer, R. P., van Oort, I. M., Kiemeney, L. A. L. M., & Ausems, M. G. E. M. (2025). Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. BJU International. https://doi.org/10.1111/bju.16916

Vancouver

Vlaming M, Koole W, van Moorselaar RJA, Bleiker EMA, van de Geer E, van Deutekom HWM, et al. Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. BJU International. 2025. doi:10.1111/bju.16916

BibTeX
@article{Vlaming2025,
  author = {Vlaming, Michiel and Koole, Wouter and van Moorselaar, R Jeroen A and Bleiker, Eveline M A and van de Geer, Ellen and van Deutekom, Hanneke W M and Ligtenberg, Marjolijn J L and van Engelen, Klaartje and Kets, C Marleen and van der Kolk, Lizet E and Schijven, Gina and Mehra, Niven and Noordzij, M Arjen and Meijer, Richard P and van Oort, Inge M and Kiemeney, Lambertus A L M and Ausems, Margreet G E M},
  title = {Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16916}
}
Kostenlos starten →